Site Editor

William J. Gradishar, MD, FACP, FASCO


Amy Tiersten, MD, on the ASPIRE Trial: A Chemotherapy-Free Front-Line Regimen in Metastatic Breast Cancer

Posted: Monday, April 8, 2024

Amy Tiersten, MD, of the Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute, discusses the clinical implications of new data from the ASPIRE trial, which suggest the combination of anastrozole, palbociclib, trastuzumab, and pertuzumab may provide a chemotherapy-free front-line regimen for patients with previously untreated hormone receptor-positive, HER2-positive metastatic breast cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.